Rosetta Genomics Ltd. and U.S. Genomics Inc. announced today the signing of a discovery and co-development agreement for a microRNA-based, non-invasive early detection test for lung cancer. This collaboration combines U.S. Genomics' patented Trilogy 2020 platform and Direct miRNA assay with Rosetta Genomics' proprietary microRNAs. By using Rosetta Genomics' newly discovered microRNAs as biomarkers, together with U.S. Genomics' patented technology for sensitive molecular-level detection and quantitation, the two companies are working to create a new molecular diagnostic test to accurately identify lung cancer using a sputum or blood sample.
PR Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Abbott Receives European Approval for Two Pediatric Devices
The devices have already received FDA clearance.
Thirteen States Support Ohio Attorney General’s Bid to Block Bellwether Opioid Trial
“States are in the best position to enter into global settlements and to protect all communities through statewide implementation of policy and ensuring equitable distribution of available funds,” one brief stated.
FDAnews Device Daily Bulletin
ROSETTA GENOMICS LTD. AND U.S. GENOMICS INC. ANNOUNCE COLLABORATION AGREEMENT
May 25, 2006
